ABSTRACT: Cerebral edema in diabetic ketoacidosis (DKA-CE) occurs primarily in children and can develop during DKA therapy. The treatment factors contributing to DKA-CE remain elusive. Our objectives were to characterize an age-appropriate DKA mouse model and to determine which DKA therapies contribute to DKA-CE. Juvenile mice were briefly fed a high-fat diet and injected with two pancreatic ␤-cell toxins: streptozocin and alloxan. Severe insulin and leptin deficiencies associated with hyperosmolar ketoacidosis rapidly developed, indicating DKA. DKA mice were treated with re-hydration Ϯ insulin and brain water content (BWC) measured as an indicator of DKA-CE. As expected, glucose and ␤-OH-butyrate corrected in DKA mice that received rehydration and insulin. BWC significantly increased above control levels only in DKA mice that received combined insulin and bicarbonate therapy, indicating the development of DKA-CE. Microscopically, DKA-CE brains had perineuronal and perivascular edema, with microvacuolation in the white matter tracts. These results indicate that insulin-deficient juvenile mice develop biochemical changes that are similar to those of DKA in children. Increased BWC was observed only in DKA mice that received combined insulin and bicarbonate therapy, suggesting that rapid systemic alkalinization in the presence of insulin may contribute to DKA-CE. (Pediatr Res 61: 301-306, 2007) 
D
KA is an emergency condition caused primarily by a severe lack of insulin that results in high blood glucose levels and an accumulation of acidic ketones in the blood (1, 2) . DKA-CE is a rare but potentially devastating complication in children that occurs within the first day of therapy (3) (4) (5) . The mortality associated with DKA-CE is estimated at 21-25% and significant neurologic morbidity at 10 -26% (3). Despite high levels of mortality and neurologic morbidity associated with DKA-CE, the etiology of DKA-CE remains poorly understood.
The cause of DKA-CE is a source of considerable debate (1, 6, 7) . The mechanisms proposed to elicit DKA-CE include increases in hydrostatic and/or decreases in osmotic pressure, increases in blood brain barrier permeability, loss of cerebral vascular autoregulation and subsequent changes in cerebral blood flow, production of intracellular osmoles in brain cells, and/or intracranial acidosis. Despite an abundance of theories on the pathophysiology of DKA-CE, there is little evidence to support any particular mechanism.
Clinical studies have linked newly diagnosed diabetes, young age, low blood CO 2 , high blood urea nitrogen, and administration of bicarbonate to the development of DKA-CE (5, 8, 9) . While these epidemiologic studies may identify children at risk for developing of DKA-CE, animal translational studies will provide insight into the cellular mechanisms contributing to DKA-CE. To date, animal studies on DKA-CE have been limited by a lack of age-appropriate animal models. The aims of this study were to characterize a juvenile mouse model of DKA and to determine which DKA therapeutic manipulations may contribute to DKA-CE.
MATERIALS AND METHODS
This study was approved by the University of Western Ontario Animal Care Committee in accordance with the Guidelines of the Canadian Council on Animal Care.
Mouse model of DKA. Juvenile male C57BL/6 mice, aged 20 -21 d, were fed a high-fat diet (Research Diets Inc., New Brunswick, NJ) for 14 d. Mice were then fasted for 16 h (10), weighed, and randomly assigned to either control or DKA groups. Each mouse in the DKA group received a 0.25 mL intraperitoneal (i.p.) injection containing STZ (200 mg/kg) and ALX (200 mg/kg). STZ/ALX was dissolved by cold citrate buffer (10 mM; pH 4.5) in glass immediately before injection. Control mice received the same volume of citrate buffer only. Glucose and ␤-OH-butyrate levels were measured from tail vein blood 72 h postinjection with a glucometer (Lifescan, Burnaby, BC, Canada) (11) and ketone meter (Abbot Laboratories, Bedford, MA), respectively. Serum ␤-OH-butyrate measured from DKA patients with this ketone meter correlate with laboratory ␤-OH-butyrate values (12, 13) .
Blood chemistry. Following anesthesia with an i.p. injection of ketamine (85-150 mg/kg) containing xylazine (8 -15 mg/kg), blood was obtained by intracardiac puncture for analysis of blood electrolytes, urea, and osmolality. Blood gases were not measured as the deep anesthesia required for intracar-diac blood sampling resulted in altered respiratory rates and hence, artifactual changes in CO 2 and pH.
Pancreatic H&E staining and immunohistochemistry. For H&E staining, 10 m pancreatic cryosections were fixed in cold acetone for 5 min then rinsed in water. Sections were exposed to CAT hematoxylin for 2 min, and then rinsed in water for 45 s. Sections were placed in Tacha's bluing solution for 30 s, and then rinsed with water for 10 min. Finally, sections were dipped in eosin Y three times before dehydration in ethanol and xylene. Slides were mounted with Permount (Fisher Scientific, Nepean, ON, Canada). For immunohistochemistry, pancreatic cryosections were thawed and then fixed in 4% paraformaldehyde (PFA) for 15 min. Following a wash in PBS, cells were permeabilized with 0.1% Triton X-100 for 10 min and then blocked with 5% BSA and 10% goat serum for 30 min. Pancreatic sections were incubated with guinea pig anti-insulin (1:50) and mouse anti-glucagon (1:2000) overnight at 4°C. After several PBS washings, sections were incubated with goat antimouse conjugated to FITC (1:50) and goat anti-guinea pig conjugated to TRITC (1:50) for 2 h at room temperature. Slides were washed in PBS and then mounted in Vectashield (Vector Laboratories, Burlingame, CA).
Insulin and leptin ELISA. Pancreatic and serum insulin were measured using an ultrasensitive mouse insulin ELISA kit (ALPCO Diagnostics, Windham, NH). Pancreatic insulin was determined simultaneously with pancreatic DNA and normalized as nanograms per microgram DNA. Serum leptin was measured using a mouse/rat leptin ELISA kit (ALPCO Diagnostics).
DKA treatment protocols. DKA was established by glucose and ␤-OHbutyrate testing, followed by administration of one of four treatment protocols: 1) 3 mL of 77 mM NaCl, 2) 3 mL of 77 mM NaCl with insulin, 3) 3 mL of 77 mM NaHCO 3 , 4) 3 mL of 77 mM NaHCO 3 with insulin. Intravenous access is exceedingly difficult in these small, dehydrated mice. Thus, rehydration solutions Ϯ insulin was given as a single i.p. injection allowing for slow systemic adsorption. The concentration of insulin (1.0 U R, 1 U NPH) administered to mice is exaggerated to account for reduced human insulin responsiveness in rodents (14) . All mice were killed 2 h posttreatment for analysis of serum biochemistry and DKA-CE.
Brain water content (BWC). Mice were euthanized and the brains were rapidly excised and immediately weighed. The brains were placed in an oven at 60°C for 5 d, and then reweighed. Brain weight was found to be constant at this time with no further decreases. BWC was calculated with the following formula: L/kg (dry weight) ϭ [(wet mass -dry mass (mg)) ϫ (1 mL/1000 mg) ϫ (1 L/1000 mL)]/dry mass (kg). Increases in BWC have been shown previously to correlate well with both elevations in intracranial pressure and abnormalities on brain histopathology (15) .
Neuropathological analysis. Deep anesthesia was induced with ketamine and xylazine, and mice were perfused with 4% PFA in the left ventricle via midline thoracotomy. Brains were removed and immersed in PFA for 24 h at 4°C, then rinsed in PBS two to three times a day for 3 d. Brains were immersed in 70% ethanol for 24 h before paraffin embedding and sectioning. H&E staining was conducted as noted above. Neuropathological findings were identified by two blinded observers.
Materials and data analysis. Unless otherwise stated, all chemicals were obtained from Sigma Chemical Co. (St. Louis, MO). Statistical significance (p Ͻ 0.05) was assessed with SigmaStat (Systat Software, San Jose, CA). Data are presented as mean Ϯ SEM.
RESULTS
Of 279 mice injected with STZ/ALX, 228 mice had sufficient DKA for further experimentation (glucose Ն20 mM; ␤-OH-butyrate Ն2.0 mM). Biochemical analysis of blood from these DKA mice 72 h postinjection of STZ/ALX showed significantly elevated glucose, ␤-OH-butyrate, urea, and osmolality (Table 1) . Serum glucose and osmolality positively correlated (correlation coefficient ϭ 0.847, p Ͻ 0.05; R 2 ϭ 0.72; n ϭ 37). DKA mice also had significantly decreased sodium, chloride, and bicarbonate (Table 1) . Serum bicarbonate and ␤-OH-butyrate negatively correlated (correlation coefficient ϭ -0.651, p Ͻ 0.05; R 2 ϭ 0.42; n ϭ 37). ␤-OHbutyrate Ͼ2.0 mM correlated with a bicarbonate Յ14 mM. Serum creatinine levels from DKA mice were 24 -54 M (n ϭ 3), indicating normal renal function (16) .
DKA mice were lethargic and anorexic, and wet patches were observed in their cages due to presumed osmotic diuresis. The average weights of control and DKA mice 72 h postinjection were significantly different at 23.7 Ϯ 0.2 g (n ϭ 88) and 18.5 Ϯ 0.2 g (n ϭ 165), respectively (p Ͻ 0.001, Mann-Whitney rank sum test). Control mice gained 2.1 Ϯ 0.1 g over the 72 h, while the DKA mice lost an average of 3.0 Ϯ 0.1 g (p Ͻ 0.001, Mann-Whitney rank sum test).
Pancreatic sections from DKA mice confirmed a reduction in insulin containing ␤-cells (n ϭ 3 mice/group). H&E staining revealed morphologically normal islets in pancreatic sections from control mice (Fig. 1A) , whereas pancreatic islets from DKA mice showed signs of hyperplasia with numerous small cells forming disorganized islets (Fig. 1B) . Pancreatic islets from control mice stained well for insulin and glucagon (Fig. 1C) . In contrast, DKA mice had pancreatic islets which stained weakly for insulin, but maintained strong staining for glucagon (Fig. 1D) . Destruction of pancreatic ␤-cells in DKA mice correlated with significantly decreased insulin [pancreatic-DKA, 0.2 Ϯ 0.1 ng/g DNA; control, 7.2 Ϯ 1.5 ng/g DNA, n ϭ 6 -12 (Fig. 1E) ; serum-DKA, 0.02 Ϯ 0.003 nmol/L; control, 0.32 Ϯ 0.07 nmol/L, n ϭ 6 -10 ( Fig. 1 F) ].
Leptin is a circulating peptide released by adipocytes and involved in short-term energy homeostasis. Serum leptin is reduced in children with type-1 diabetes presenting with DKA (17) and serum leptin was also significantly decreased in DKA mice (DKA, 0.4
DKA mice had a serum glucose concentration of 31.4 Ϯ 0.3 mM and ␤-OH-butyrate concentration of 4.1 Ϯ 0.1 mM ( Fig.  2 ; n ϭ 23-30 mice/group). Treatment with saline rehydration did not significantly alter glucose (30.6 Ϯ 0.8 mM) or ␤-OHbutyrate (4.0 Ϯ 0.2 mM). Administration of a bicarbonate solution resulted in mildly elevated glucose (32.4 Ϯ 0.4 mM) and ␤-OH-butyrate (5.0 Ϯ 0.1 mM). In contrast, the addition of insulin to the saline rehydration solution resulted in a significant reduction in glucose (15.5 Ϯ 2.4 mM) and ␤-OHbutyrate (2.7 Ϯ 0.3 mM). Treatment with both a bicarbonate rehydration solution and insulin also resulted in a significant reduction in glucose (7.3 Ϯ 1.2 mM) and ␤-OH-butyrate (3.2 Ϯ 0.3 mM). Comparison of all groups for glucose concentration at 2 h posttreatment showed that the rehydration only groups (saline or bicarbonate) were significantly different to those 302 rehydration groups that also received insulin (p Ͻ 0.05, ANOVA with Dunn's multiple comparison procedure). There were no significant differences in glucose concentration between groups that received saline ϩ insulin or bicarbonate ϩ insulin. Comparison of all groups for ␤-OH-butyrate concentration at 2 h posttreatment showed that the bicarbonate rehydration only group was significantly different from all other treatment groups (p Ͻ 0.05, ANOVA with Dunn's multiple comparison procedure).
BWC was measured as an indicator of DKA-CE after rehydration Ϯ insulin therapy ( Fig. 3A ; n ϭ 23/group). The BWC of DKA mice was 3.43 Ϯ 0.05 L/kg, significantly lower than the control BWC (3.72 Ϯ 0.01 L/kg). DKA mice treated with saline rehydration had a BWC of 3.65 Ϯ 0.01 L/kg, while DKA mice treated with a bicarbonate rehydration solution was 3.64 Ϯ 0.03 L/kg. DKA mice treated with saline and insulin had a BWC of 3.71 Ϯ 0.02 L/kg. Significantly, the BWC of DKA mice treated with bicarbonate and insulin increased well above control (3.80 Ϯ 0.02 L/kg), indicating development of DKA-CE. Following deep anesthesia and removal of overlying tissues, DKA-CE in situ was observed through the transparent immature skull in DKA mice treated with bicarbonate and insulin (Fig. 3C) . The brains of DKA-CE mice were pale in appearance and had distorted fissures with less apparent pial blood vessels, compared with brains of control (Fig. 3B) .
In a subgroup of animals, effective osmolalities were calculated for each treatment group (Table 2) . Effective osmolality was significantly different in groups treated with rehydration alone (saline 320 Ϯ 2 mOsmol and bicarbonate 317 Ϯ 3 mOsmol) versus those treated with rehydration and insulin (saline and insulin 303 Ϯ 2 mOsmol; bicarbonate and insulin (1) NaCl (-), (2) NaHCO 3 (OE-OE), (3) NaCl ϩ insulin (e-e), or (4) NaHCO 3 ϩ insulin (-). Blood glucose and ␤-OH-butyrate levels in DKA mice injected with NaCl alone did not significantly differ from control. In contrast, blood glucose and ␤-OH-butyrate levels significantly decreased in both groups that received rehydration and insulin (*p Ͻ 0.001, paired t test or Wilcoxon rank signed test). 
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CEREBRAL EDEMA IN DIABETIC KETOACIDOSIS 307 Ϯ 3 mOsmol). There was no significant difference in effective osmolality between DKA mice treated with saline and insulin or bicarbonate and insulin. Despite the same effective osmolality between the treatment groups that received insulin, only DKA mice treated with bicarbonate and insulin developed DKA-CE.
Microscopic examination of paraffin-sectioned DKA-CE brain sections, obtained from DKA mice that received bicarbonate and insulin therapy, revealed edema in the perivascular and perineuronal spaces as well as microvacuolation in the white matter tracts, compared with control brains (n ϭ 3 mice/group). These neuropathological findings were most prevalent in the basal ganglia (Fig. 4) , although, subtle differences in both perineuronal and perivascular edema in cortical and hippocampal regions of the DKA-CE brains were also observed (data not shown).
DISCUSSION
In this study, juvenile mice were briefly fed a high fat diet and injected with STZ/ALX on postnatal d 35, around the time of puberty for C57BL/6 mice (18) . Published DKA models use adult animals and vary considerably depending on the species, the pancreatic toxin used, the route of drug administration, and the dosage (10) . The prevalent DKA model uses adult rats injected with STZ (45-200 mg/kg) (14, 19, 20) . DKA was also observed in adult rats 48 h after injection with ALX (21) , and in adult rabbits and dogs injected with STZ/ALX (22, 23) . The only mouse study to demonstrate ketosis involved STZ-treated adult mice fed a high-fat diet for 16 wk (24) . We characterized a juvenile mouse model of DKA, as DKA-CE is almost exclusively a pediatric pathology (2, 25) . To elicit DKA in juvenile mice, we used STZ/ALX. STZ damages ␤-cells via oxidant stress and DNA alkylation (10), whereas ALX toxicity involves oxidation of thiol groups, inhibition of glucokinase, free radical generation, and disturbances in intracellular calcium homeostasis (26) . Both STZ and ALX were required to induce DKA in our mice, likely due to rapid ␤-cell turnover in juvenile rodents (27) . It is unlikely that administration of STZ/ALX directly contributed to the development of DKA-CE, as these pancreatic toxins do not significantly affect brain physiology with acute systemic exposure (28 -31) .
Immature rats rarely develop ketosis in STZ-induced diabetes (20) , likely due to insufficient body fat stores and/or resistance to fat metabolism (32) . To increase the probability that our juvenile mice would develop ketosis, we fed our juvenile mice a high-fat diet before injecting them with STZ/ ALX. Seventy-two hours after injection, elevated serum ␤-OH-butyrate was measured within the range of ␤-OHbutyrate values reported from children with DKA (11, 33) . Moreover, serum leptin was reduced in untreated DKA mice as observed in children with type-1 diabetes presenting with DKA (17) . In contrast, leptin increases in untreated DKA in both human adults and in an adult mouse model of diabetes (24, 34) .
Juvenile mice injected with STZ/ALX lost weight and developed osmotic diuresis, anorexia, lethargy, and dehydration. Moreover, biochemical analysis of serum obtained from DKA mice revealed hyperosmolar ketoacidosis associated 
All groups represent an n ϭ 12. Effective osmolalities were calculated by [Na ϩ (mmol/L) ϫ 2] ϩ glucose (mmol/L). All treatment groups received 3 ml of rehydration fluid. There are significant differences between DKA mice treated with rehydration only (NaCl or NaHCO 3 ) and those groups treated with rehydration and insulin (NaCl ϩ insulin or NaHCO 3 ϩ insulin). There was no significant difference between the two groups that were treated with rehydration and insulin (NaCl ϩ insulin or NaHCO 3 ϩ insulin). ANOVA with Student-Newman-Keuls multiple comparison test, p Ͻ 0.05. with severe insulin deficiency. Our results demonstrate that STZ/ALX injection in juvenile mice results in a pattern of symptoms and biochemical abnormalities that are similar to that of DKA in children with type 1 diabetes. Glucose and ␤-OH-butyrate levels corrected with rehydration and insulin therapy.
DKA-CE in children can develop within hours after starting DKA treatment (4, 5) , however, DKA-CE has also been observed with imaging in children upon DKA presentation (4, 5, (35) (36) (37) . The causes of DKA-CE before therapy are not known but might be related to free water consumption by children with DKA before presentation to hospital (35) . Free water was not actively administered to the DKA mice in our study, which could explain the significantly lower BWC than control mice. Our model therefore examined only DKA-CE associated with DKA treatment (5, 6, 8) . Of note, the DKA treatments in this study were administered as a single i.p. injection and may have resulted in more rapid intravascular expansion than would occur clinically with controlled i.v. treatment. Nonetheless, when DKA mice were treated with either saline or bicarbonate rehydration solution, BWC was not significantly different from either control or DKA. The BWC increased to control levels, however, when saline rehydration was combined with insulin therapy. This latter result is probably not clinically significant, as the fixed volume within the intracranial vault should accommodate a BWC up to control levels. The only treatment group to develop significant DKA-CE, defined as a significant increase BWC over control levels, was DKA mice that received combined insulin and bicarbonate therapy.
The DKA-CE observed with combined bicarbonate and insulin therapy reflects both overhydration of the cerebral parenchyma (3) and direct cellular swelling (7). Indeed, edema was evident in both the perineuronal and perivascular spaces and as microvacuolation of the white matter tracts. These neuropathological changes were most prevalent in the basal ganglia, a finding that correlates with imaging studies on children with DKA-CE (38, 39) .
Decreases in effective osmolality did not correlate with increases in BWC above control values. Effective osmolality significantly decreased in DKA mice that received rehydration and insulin, compared with the groups that received only rehydration. The effective osmolalities of the treatment groups that received saline and insulin or bicarbonate and insulin were not significantly different, yet DKA-CE only occurred when a combination of bicarbonate and insulin were administered. Although the development of DKA-CE in this study did not correlate with decreases in effective osmolality, rapid decreases in effective osmolality would exacerbate DKA-CE (7).
Bicarbonate administration in DKA might cause a paradoxical acidosis in brain, as systemic bicarbonate therapy elevates serum CO 2 that rapidly diffuses across the blood brain barrier (40) . Rapid acidosis in brain secondary to CO 2 accumulation may elicit DKA-CE, perhaps via hyperemia from the acid altering effects on cerebral blood flow (41) . Cerebral hypoxia may also occur from bicarbonate administration in DKA (23) . If the DKA-CE elicited in this study with combined bicarbonate and insulin therapy was specifically due to paradoxical acidosis in brain and/or cerebral hypoxia, then the DKA mice treated with bicarbonate alone should have also developed DKA-CE. As the BWC was not significantly elevated in the bicarbonate group, additional mechanisms specific to insulin must contribute to DKA-CE. Indeed, plasma bicarbonate and pH markedly affect the dissolution of insulin and, hence, the bioavailability of the active insulin monomer (42) .
These animal data suggest that bicarbonate should not be used to correct the metabolic acidosis in children receiving insulin therapy for DKA. Bicarbonate therapy does not improve the outcome of severe DKA (43) and an association between bicarbonate administered to children with DKA and the subsequent development of DKA-CE has been suggested (5). This adverse relationship between bicarbonate and DKA-CE had not been reproduced experimentally in juvenile animals, however, as we have done in this report. The finding that BWC was elevated in DKA mice treated with bicarbonate and insulin suggests that rapid systemic alkalinization may exacerbate brain swelling, but requires priming with insulin. The precipitating factors that predispose children to DKA-CE in the absence of bicarbonate administration remain unclear, but may include a combination of factors, including cerebral edema on presentation, insulin administration and rapid correction in systemic pH.
In summary, we have characterized a juvenile mouse model of DKA that develops symptoms and biochemical changes that are similar to those observed in children with DKA. DKA was corrected in mice by rehydration and insulin therapy. Moreover, our data demonstrate the potential adverse outcome of DKA-CE with combined insulin and bicarbonate therapy. As always, caution must be exercised with extrapolation of animal data to humans, although further experiments using this mouse model may help clarify the causes of DKA-CE and lead to the identification of safer therapeutic maneuvers and/or pharmacological targets for neuroprotection.
